electroCore (ECOR) obtains a new patent for the treatment of stroke and TIA

Enter Wall Street with Street Insider Premium. Claim your 1-week free trial here.

electroCore, Inc., (NASDAQ: ECOR), a commercial-stage bioelectronic medicine company, today announced that the United States Patent and Trademark Office (USPTO) has issued U.S. Patent No. 11,191,953 to the society, relating to the treatment of stroke symptoms.

The recently issued patent relates to methods of treating the acute symptoms of a stroke or transient ischemic attack (TIA), a temporary period of symptoms similar to those of a stroke, according to a treatment paradigm based on the application of a transcutaneous drug not impulse or invasive electrical stimulation.

This newly authorized patent belongs to the Company and reinforces the development efforts associated with certain trials initiated by researchers in the field of stroke, which is the second leading cause of death and the third leading cause of disability in the world. Earlier this year, the Company announced the full recruitment of the TR-VENUS Non-invasive Vagal Nerve Stimulation (nVNS) study for the acute treatment of stroke. “We are delighted with this latest patent grant for another important potential use of electroCore’s non-invasive approach to treat patients with vagus nerve stimulation which has devastating effects on people’s lives,” commented JP Errico, founder, board member and investor of the Company, who was also co-inventor of the new patent. “Each year, approximately 15 million people worldwide suffer from stroke, and our non-invasive vagus nerve stimulator technology can be an effective acute treatment to reduce the damaging effects on the brains of these patients. With ongoing trials initiated by stroke researchers and our recently issued patent, we are eager to understand the potential role of nVNS in the stroke patient care paradigm around the world.

About Antoine L. Cassell

Check Also

IMU-838 treatment associated with low rate of confirmed disability worsening in relapsing MS

Recently reported interim data from the Phase 2 EMPhASIS trial (NCT03846219) of Immunic’s investigational agent, …

Leave a Reply

Your email address will not be published.